title: Tirofiban-induced acute profound thrombocytopenia: what is the optimal approach to treatment?
authors.affiliation: Department of Cardiology, Siyami Ersek Thoracic and Cardiovascular Surgery Center, Training and Research Hospital , Istanbul , Turkey .
authors.forename: Yalcin
authors.initials: Y
authors.lastname: Velibey
authors.forename: Yalcin
authors.initials: Y
authors.lastname: Golcuk
authors.forename: Ahmet
authors.initials: A
authors.lastname: Ekmekci
authors.forename: Servet
authors.initials: S
authors.lastname: Altay
authors.forename: Erkan
authors.initials: E
authors.lastname: Gunay
authors.forename: Mehmet
authors.initials: M
authors.lastname: Eren
mesh_terms: D000328:Adult; D006801:Humans; D016756:Immunoglobulins, Intravenous; D008297:Male; D010975:Platelet Aggregation Inhibitors / Q000009:adverse effects*; D010976:Platelet Count; D013921:Thrombocytopenia / Q000139:chemically induced* / Q000175:diagnosis / Q000628:therapy; D000077466:Tirofiban; D016896:Treatment Outcome; D014443:Tyrosine / Q000009:adverse effects / Q000031:analogs & derivatives*
chemical_list: D016756:Immunoglobulins, Intravenous; D010975:Platelet Aggregation Inhibitors; D014443:Tyrosine; D000077466:Tirofiban